DrugPatentWatch Database Preview
Patent: 7,700,299
» See Plans and Pricing
Summary for Patent: 7,700,299
| Title: | Method for predicting the response to a treatment |
| Abstract: | The invention is related to a method of predicting the response to a treatment with a HER inhibitor in a patient comprising the steps of assessing a biomarker or a combination of biomarkers selected from the group consisting of amphiregulin, an epidermal growth factor, a transforming growth factor alpha, and a HER2 biomarker in a biological sample from the patient and predicting the response to the treatment with the HER inhibitor in the patient by evaluating the results of the first step. Further uses and methods wherein these markers are used are disclosed. |
| Inventor(s): | Moecks; Joachim (Mannheim, DE), Strauss; Andreas (Penzberg, DE), Zugmaier; Gerhard (Stuttgart, DE) |
| Assignee: | Hoffmann-La Roche Inc. (Nutley, NJ) |
| Application Number: | 11/438,033 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,700,299
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | PERJETA | pertuzumab | VIAL; SINGLE-USE | 125409 | 001 | 2012-06-08 | Start Trial | Hoffmann-La Roche Inc. (Nutley, NJ) | 2025-08-12 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 7,700,299
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 201102688 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2007019899 | Start Trial |
| United States of America | 2007037228 | Start Trial |
| United States of America | 2010112603 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
